Berlin, June 2, 2026 — A landmark clinical trial has delivered promising news for patients battling advanced squamous non-small cell lung cancer (NSCLC), a particularly aggressive form of the disease with few effective treatment options. The latest results from the HARMONi-6 trial demonstrate that ivonescimab, a first-in-class PD-1/VEGF bispecific antibody developed by Akeso, combined with chemotherapy, significantly improves overall survival (OS) compared to the current standard of care. This breakthrough, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, marks a potential turning point for a patient population that has historically faced limited therapeutic advances.
The findings build on earlier interim data showing the combination therapy also prolonged progression-free survival (PFS), reinforcing ivonescimab’s role as a promising new weapon in the fight against squamous NSCLC—a subtype accounting for roughly 25% of all lung cancers and responsible for an estimated 55,000 U.S. Cases annually. With lung cancer remaining the leading cause of cancer-related deaths worldwide, the new data offer a glimmer of hope for patients who have long faced grim prognoses.
Dr. Helena Fischer, Editor of Health at World Today Journal, breaks down the implications of this study and what it means for patients, clinicians, and the future of lung cancer treatment.
How Ivonescimab Works: A Dual-Targeted Approach
Ivonescimab is not your typical cancer therapy. Unlike traditional monoclonal antibodies that target a single pathway, this drug is a bispecific antibody, meaning it simultaneously blocks two critical molecular targets: PD-1 (programmed death-1) and VEGF (vascular endothelial growth factor).
PD-1 inhibitors, such as pembrolizumab and tislelizumab, have revolutionized cancer treatment by releasing the immune system’s brakes, allowing T-cells to attack tumors. However, many patients—especially those with squamous NSCLC—either do not respond to these drugs or develop resistance over time. VEGF, promotes the formation of new blood vessels that supply tumors with nutrients, making it a key driver of cancer progression.
By inhibiting both PD-1 and VEGF in a single molecule, ivonescimab aims to enhance anti-tumor immunity while starving tumors of their blood supply. Early-phase trials, including the HARMONi-A and AK112-202 studies, had already suggested this dual approach could improve outcomes in NSCLC patients, particularly those whose tumors had progressed after initial EGFR-targeted therapies. The HARMONi-6 trial now extends these findings to the first-line setting, where treatment options are most critical.
HARMONi-6 Trial: Key Findings and What They Mean
The phase 3 HARMONi-6 trial randomized 532 patients with untreated advanced squamous NSCLC—all from China—to receive either:
- Ivonescimab plus chemotherapy (carboplatin plus nab-paclitaxel or gemcitabine), or
- Tislelizumab (Tevimbra) plus chemotherapy, the current standard of care.
According to the ASCO 2026 press release, the primary endpoint of progression-free survival (PFS) was met in the first interim analysis (reported in April 2025), with ivonescimab plus chemotherapy “decisively beating” the tislelizumab arm. Now, the latest data reveal a statistically significant improvement in overall survival (OS), a far more meaningful metric for patients.
Key takeaways from the updated results:
- The benefit was observed regardless of PD-L1 expression, a protein often used to predict response to PD-1 inhibitors. Here’s particularly notable because squamous NSCLC patients frequently have low or negative PD-L1 status, making them less likely to benefit from PD-1 monotherapy.
- The trial included patients with stage IV or recurrent disease, reflecting real-world clinical scenarios where first-line treatment decisions are most consequential.
- While the study was conducted in China, the findings align with prior global trials (e.g., HARMONi-A), suggesting potential applicability to broader populations—though further data from international cohorts are awaited.
“This is the first large prospective trial to prove that an anti-PD-1/VEGF bispecific therapy plus chemotherapy is superior to the established standard of PD-1 inhibitor plus chemotherapy in patients with advanced squamous lung cancer,” said David R. Spigel, MD, FASCO, President and Chief Medical Officer at the Sarah Cannon Research Institute and an ASCO lung cancer expert. “While this study included participants from China and efficacy data from global populations are pending, it provides a vital new path forward for patients with these difficult-to-treat cancers who have limited treatment options.”
Why This Matters: Squamous NSCLC and the Treatment Gap
Squamous NSCLC is distinct from other lung cancer subtypes in critical ways:
- Higher smoking rates: Unlike adenocarcinoma (the most common subtype), squamous NSCLC is strongly linked to tobacco use, affecting patients who may already face comorbidities like COPD or cardiovascular disease.
- Poorer prognosis: Historically, squamous NSCLC has shown lower response rates to immunotherapy compared to other NSCLC types, partly due to its unique tumor microenvironment.
- Limited targeted options: While adenocarcinoma patients may benefit from EGFR or ALK inhibitors, squamous NSCLC lacks comparable targeted therapies, leaving chemotherapy and PD-1 inhibitors as the mainstays.
The HARMONi-6 results address these challenges by demonstrating that ivonescimab’s dual mechanism may overcome some of the resistance seen with PD-1 monotherapy. “For patients with squamous NSCLC, every additional month of survival is meaningful,” notes Fischer. “This trial suggests that combining immunotherapy with anti-angiogenic therapy could be a game-changer, especially for those who don’t express high PD-L1.”
Next Steps: What Happens Now?
The full HARMONi-6 dataset, including mature OS and safety data, will be presented at upcoming medical conferences, with regulatory submissions expected in 2027. Akeso, the developer of ivonescimab, has already shared plans to expand the trial into global populations, including the U.S. And Europe, to confirm the findings across diverse patient groups.
In the meantime, clinicians and patients can:
- Monitor ASCO and Akeso’s official communications for updates on regulatory filings and trial expansions.
- Consult clinicaltrials.gov for enrollment in ongoing or upcoming NSCLC studies, including HARMONi-6 (if still open) or related trials.
- Engage with lung cancer advocacy groups, such as the Lung Cancer Foundation of America, for resources and support.
Expert Perspective: What This Means for Patients
Dr. Fischer emphasizes that while the results are encouraging, several questions remain:
- Real-world applicability: Will the benefits observed in China translate to other regions with different healthcare systems and patient profiles?
- Safety profile: Bispecific antibodies can carry unique side effects, such as hypertension or proteinuria (due to VEGF inhibition). Long-term data will be critical.
- Cost and access: If approved, how will ivonescimab’s pricing compare to existing therapies, and will it be accessible in lower-resource settings?
“For now, patients should continue working closely with their oncologists to explore all available options, including clinical trials,” Fischer advises. “This study is a major step forward, but the journey to broader adoption—and better outcomes—will take time.”
Key Takeaways
- The HARMONi-6 trial shows ivonescimab plus chemotherapy improves overall survival in first-line advanced squamous NSCLC, regardless of PD-L1 status.
- Ivonescimab is a PD-1/VEGF bispecific antibody, offering a dual mechanism to enhance immunotherapy efficacy.
- Squamous NSCLC is a difficult-to-treat subtype with limited targeted options, making this breakthrough particularly significant.
- Regulatory submissions are expected in 2027, with global trial expansion underway.
- Patients should stay informed through ASCO, Akeso, and clinicaltrials.gov for updates.
FAQ: What Patients Need to Know
Q: Is ivonescimab already available?
A: Not yet. The drug is still in late-stage trials, with regulatory approval expected in 2027 if further data confirm its benefits.
Q: Will this work for all types of lung cancer?
A: The current data focus on squamous NSCLC. Trials for other subtypes (e.g., non-squamous NSCLC) are ongoing but not yet published.
Q: Are there side effects I should be aware of?
A: Common side effects of PD-1 inhibitors include fatigue and rash, while VEGF inhibition may cause hypertension or kidney issues. The full safety profile will be detailed in future reports.
Q: How can I access this treatment now?
A: If eligible, patients can enroll in clinical trials like HARMONi-6 (check clinicaltrials.gov) or discuss experimental therapies with their oncologist.
Q: What’s the difference between PFS and OS?
A: PFS (progression-free survival) measures how long a treatment delays tumor growth, while OS (overall survival) tracks how long patients live after treatment. OS is the gold standard for cancer trials.
— Dr. Helena Fischer
Editor, Health | World Today Journal
Next Steps: The next major checkpoint will be the 2026 European Society for Medical Oncology (ESMO) Congress, where additional HARMONi-6 data and global trial updates are expected. In the meantime, patients and clinicians can follow ASCO and Akeso’s official communications for real-time developments.
Share your thoughts: How might this breakthrough impact lung cancer care in your region? Comment below or share this article with a healthcare provider.